Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 4, 2019
Reporting Period: Event-based report regarding a specific corporate announcement on June 4, 2019.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding a corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes or operational updates were reported in this document. The filing solely announces a scheduled presentation by the Company's Director of Neuroscience, CJ Barnum, Ph.D., regarding the Alzheimer's drug candidate XPro1595 at the TNF Conference.
Guidance, Outlook, and Risks
Management Commentary: The Company confirmed the presentation of its Alzheimer's drug candidate XPro1595 at the TNF Conference on June 4, 2019.
Risks and Contingencies: No specific risks or contingencies were detailed in this filing.
Unusual Items: None reported.
Investor Verification Checklist
- Verify the content and data presented in the press release (Exhibit 99.1) regarding the XPro1595 candidate.
- Confirm the status of the TNF Conference presentation and any subsequent data releases.
- Review the Company's latest 10-K or 10-Q filings for actual financial performance metrics, as this 8-K contains no financial data.